Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
26 Apr 2021
26 Apr 2021
Historique:
received:
09
02
2021
accepted:
25
04
2021
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
29
4
2022
Statut:
epublish
Résumé
The enhanced permeability and retention effect allows for passive targeting of solid tumours by nanoparticles carrying anticancer drugs. However, active targeting by incorporation of various ligands onto nanoparticles can provide for a more selective and enhanced chemotherapeutic effect and complement the deficiencies of the passive targeting approach. Here we report on the design of the carboxyl-terminated PEGylated gold nanoparticles (AuNPs), their functionalization with anti-CD133 monoclonal antibody (mAb)
Identifiants
pubmed: 35481195
doi: 10.1039/d1ra01093j
pii: d1ra01093j
pmc: PMC9030463
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16131-16141Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts of interest to declare.
Références
Biomaterials. 2012 Feb;33(5):1663-72
pubmed: 22116000
ACS Appl Mater Interfaces. 2017 Mar 29;9(12):10472-10480
pubmed: 28276674
Materials (Basel). 2018 Jul 06;11(7):
pubmed: 29986436
Tumour Biol. 2015 Mar;36(3):1339-53
pubmed: 25680406
Int J Nanomedicine. 2016 May 02;11:1867-78
pubmed: 27194910
Anal Chem. 2006 Feb 15;78(4):1104-6
pubmed: 16478100
Clin Transl Med. 2018 Jul 9;7(1):18
pubmed: 29984391
J Control Release. 2016 Sep 28;238:58-70
pubmed: 27448444
J Phys Chem B. 2006 Aug 17;110(32):15700-7
pubmed: 16898714
PLoS One. 2019 Jun 26;14(6):e0218686
pubmed: 31242246
J Pathol. 2009 Dec;219(4):427-34
pubmed: 19621338
Anal Chem. 2007 Jun 1;79(11):4215-21
pubmed: 17458937
ACS Appl Mater Interfaces. 2013 Nov 13;5(21):10753-9
pubmed: 24095174
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
J Am Chem Soc. 2014 Feb 5;136(5):1907-21
pubmed: 24422457
Int J Pharm. 2017 Jan 10;516(1-2):61-70
pubmed: 27825867
J Chin Med Assoc. 2019 Nov;82(11):814-818
pubmed: 31469690
Int J Nanomedicine. 2019 Mar 11;14:1633-1657
pubmed: 30880970
ACS Appl Mater Interfaces. 2016 Jul 20;8(28):17793-804
pubmed: 27348241
Oncotarget. 2017 Sep 8;8(43):75756-75766
pubmed: 29088907
J Adv Res. 2018 Jun 25;15:1-18
pubmed: 30581608
Nat Biotechnol. 2015 Sep;33(9):941-51
pubmed: 26348965
World J Gastroenterol. 2013 May 7;19(17):2603-11
pubmed: 23674867
J Control Release. 2015 May 28;206:37-48
pubmed: 25758331
Theranostics. 2020 Jun 25;10(17):7921-7924
pubmed: 32685029
Clin Cancer Res. 2010 Dec 15;16(24):6139-49
pubmed: 20876255
Sensors (Basel). 2018 Jul 12;18(7):
pubmed: 30002306
Sci Rep. 2019 Oct 17;9(1):14912
pubmed: 31624285
Int J Mol Sci. 2018 Jul 06;19(7):
pubmed: 29986450
Langmuir. 2014 Sep 9;30(35):10779-84
pubmed: 25127436
Chem Soc Rev. 2020 Dec 7;49(23):8774-8789
pubmed: 33089858
Int J Nanomedicine. 2019 Jan 25;14:819-834
pubmed: 30774336
Bioconjug Chem. 2016 Oct 19;27(10):2225-2238
pubmed: 27547843
Sci Rep. 2015 Feb 04;5:8244
pubmed: 25650019
PLoS One. 2013;8(2):e56380
pubmed: 23409180
Front Immunol. 2019 Feb 01;10:133
pubmed: 30774634
Expert Opin Investig Drugs. 2009 Mar;18(3):335-48
pubmed: 19243284
FEBS Lett. 1988 Apr 25;231(2):381-4
pubmed: 3360144
Bioconjug Chem. 2006 May-Jun;17(3):603-9
pubmed: 16704197
Acta Pharmacol Sin. 2011 Aug;32(8):983-90
pubmed: 21743485
ACS Omega. 2019 Oct 17;4(18):17850-17856
pubmed: 31681893
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Eur J Radiol. 2014 Jul;83(7):1190-1198
pubmed: 24832501
Nat Mater. 2020 May;19(5):566-575
pubmed: 31932672
Mol Immunol. 2017 Nov;91:123-133
pubmed: 28898717
Med Oncol. 2012 Dec;29(4):2849-57
pubmed: 22246526
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
Curr Drug Discov Technol. 2015;12(1):3-20
pubmed: 26033233
PLoS One. 2015 Mar 30;10(3):e0122952
pubmed: 25822983
Cell Biol Int. 2020 Feb;44(2):368-380
pubmed: 31579983
Int J Pharm. 2018 Mar 1;538(1-2):105-111
pubmed: 29341915